NASDAQ:MRSN Mersana Therapeutics - MRSN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.70 -0.32 (-4.56%) (As of 02/6/2023 05:33 PM ET) Add Compare Share Share Today's Range$6.68▼$7.2250-Day Range$5.27▼$7.2552-Week Range$2.68▼$8.34Volume1.18 million shsAverage Volume1.11 million shsMarket Capitalization$668.46 millionP/E RatioN/ADividend YieldN/APrice Target$15.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Mersana Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.9% Upside$15.40 Price TargetShort InterestBearish5.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.84Based on 2 Articles This WeekInsider TradingSelling Shares$164,847 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.25) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector342nd out of 1,027 stocksPharmaceutical Preparations Industry169th out of 500 stocks 3.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.40, Mersana Therapeutics has a forecasted upside of 129.9% from its current price of $6.70.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.23% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Mersana Therapeutics has recently increased by 3.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.7 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mersana Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,847.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions92.40% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($2.25) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mersana Therapeutics (NASDAQ:MRSN) StockMersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.Read More Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comMersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian CancerJanuary 25, 2023 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsFebruary 6, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 25, 2023 | finance.yahoo.comMersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsJanuary 16, 2023 | finance.yahoo.comZai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?January 6, 2023 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected MilestonesJanuary 1, 2023 | finance.yahoo.comMersana Inks Cancer Therapy Development Deal With Merck GermanyDecember 31, 2022 | finance.yahoo.comEstimating The Fair Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN)February 6, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." December 23, 2022 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement withDecember 22, 2022 | marketwatch.comMersana Therapeutics Shares Rise 5.2% on Agreement with Merck KGaA SubsidiaryDecember 14, 2022 | finance.yahoo.comEuropean Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian CancerNovember 21, 2022 | seekingalpha.comImmunoGen, Mersana win buy ratings at Truist on ADC prospectsNovember 8, 2022 | finance.yahoo.comMersana Therapeutics to Present at Jefferies London Healthcare ConferenceNovember 7, 2022 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue EstimatesNovember 7, 2022 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial ResultsNovember 7, 2022 | tmcnet.comMersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial ResultsNovember 7, 2022 | msn.comRecap: Mersana Therapeutics Q3 EarningsNovember 7, 2022 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial ResultsNovember 2, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Mersana Therapeutics (MRSN)October 31, 2022 | finance.yahoo.comMersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022October 30, 2022 | finance.yahoo.comInvesting in Mersana Therapeutics (NASDAQ:MRSN) three years ago would have delivered you a 284% gainOctober 18, 2022 | fool.comMersana Therapeutics, Inc. (NASDAQ: MRSN)October 17, 2022 | finance.yahoo.comAre Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?October 6, 2022 | finance.yahoo.comMersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian CancerSeptember 30, 2022 | baystreet.caMersana Jumps on Launch of ONCOLOGY FACETSSeptember 30, 2022 | finance.yahoo.comMersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic MalignanciesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Company Calendar Last Earnings11/09/2021Today2/06/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.40 High Stock Price Forecast$20.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+129.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-170,060,000.00 Net Margins-1,749.59% Pretax Margin-1,749.59% Return on Equity-171.23% Return on Assets-80.76% Debt Debt-to-Equity Ratio0.28 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$40,000.00 Price / Sales16,711.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book3.96Miscellaneous Outstanding Shares99,770,000Free Float95,384,000Market Cap$668.46 million OptionableNot Optionable Beta1.74 Key ExecutivesAnna ProtopapasPresident, Chief Executive Officer & DirectorBrian DeSchuytnerChief Financial Officer & Senior Vice PresidentTimothy B. LowingerChief Science & Technology OfficerArvin YangChief Medical Officer & Senior Vice PresidentAlejandra Veronica CarvajalSecretary, Chief Legal Officer & Senior VPKey CompetitorsViking TherapeuticsNASDAQ:VKTXAltimmuneNASDAQ:ALTEmergent BioSolutionsNYSE:EBSSeres TherapeuticsNASDAQ:MCRBFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 9,334 shares on 2/2/2023Ownership: 0.049%ProShare Advisors LLCBought 2,051 shares on 2/2/2023Ownership: 0.020%Zurcher Kantonalbank Zurich Cantonalbank Bought 4,985 shares on 2/1/2023Ownership: 0.012%Anna ProtopapasSold 17,346 sharesTotal: $99,566.04 ($5.74/share)Brian DeschuytnerSold 5,131 sharesTotal: $29,451.94 ($5.74/share)View All Insider TransactionsView All Institutional Transactions MRSN Stock - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price forecast for 2023? 5 brokerages have issued 1-year target prices for Mersana Therapeutics' stock. Their MRSN share price forecasts range from $12.00 to $20.00. On average, they anticipate the company's share price to reach $15.40 in the next year. This suggests a possible upside of 119.7% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2023? Mersana Therapeutics' stock was trading at $5.86 at the beginning of 2023. Since then, MRSN stock has increased by 19.6% and is now trading at $7.01. View the best growth stocks for 2023 here. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.05. The business earned $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Mersana Therapeutics had a negative net margin of 1,749.59% and a negative trailing twelve-month return on equity of 171.23%. During the same quarter in the previous year, the company earned ($0.33) earnings per share. What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.05%), ProShare Advisors LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $7.01. How much money does Mersana Therapeutics make? Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $699.39 million and generates $40,000.00 in revenue each year. The company earns $-170,060,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. How many employees does Mersana Therapeutics have? The company employs 169 workers across the globe. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com. This page (NASDAQ:MRSN) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.